Del Mar Pharmaceuticals, Inc. (DMPI) Starts Presentation at 2nd Annual Marcum MicroCap Conference
Del Mar Pharmaceuticals is developing and commercializing cancer therapies in new orphan drug indications for patients failing modern targeted or biologic treatments. The company’s lead asset, VAL-083, is currently undergoing clinical trials in the U.S. as a potential treatment for refractory glioblastoma multiforme, the most common and aggressive form of brain cancer. VAL-083’s clinical research is sponsored by the U.S. National Cancer Institute and is currently approved for the treatment of chronic myelogenous leukemia and lung cancer in China. For more information visit the company’s Web site at www.delmarpharma.com
Let us hear your thoughts below:
The Marcum MicroCap Conference is a forum where publicly traded companies with less than $500 million in market capitalization can network with the investment community. The two-day 2016 conference will include feature presentations by CEOs and CFOs from seven principal industry sectors, expert panels moderated by industry leaders, and the opportunity to meet with management of presenting companies on a one-on-one basis. Marcum is partnered with KCSA Strategic Communications to present this year's Marcum MicroCap Conference.
This entry was posted in
Marcum MicroCap. Bookmark the
permalink.
